Pomalidomide is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator.[medical citation needed]
Pomalidomide was approved in February 2013, by the US Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma. It has been approved for use in people who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy. It received a similar approval from the European Commission in August 2013.